Health care investors are moving out of sectors that could be hit with federal funding cuts, or become vilified in the media.
Telehealth companies have proliferated rapidly in recent years, and so have mergers and acquisitions targeting them. In the first half of 2017, 11 deals have been made public for U.S.[...]
Last year we predicted that, after a busy 2016, Stryker Corporation (NYSE: SYK), the Michigan-based medical device giant, would have a quiet 2017 as it integrated its new product lines.[...]
Mergers and acquisitions in the Laboratories, MRI and Dialysis sector increased nearly 30% through late June, compared with the same time last year. Fourteen acquirers inked 22 acquisitions, and most of[...]
Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.
Health Care M&A Weekly Deals, The Week Ending June 9, 2017
A recent Managed Care deal may portend more troubling news for the struggling industry. Lately, mergers and acquisitions in the sector have been driven by firms exiting the market due to rising costs. Even a network as large as Tenet Healthcare Corporation (NYSE: THC) cited rising costs and unanticipated losses as reasons for shedding its Health Plan Business.
Mergers and acquisitions in digital health are surging, thanks to the amount of healthcare data being generated and analyzed.
Health Care M&A Weekly Deals, The Week Ending June 2, 2017
Aziyo Biologics, Inc. is finally gaining some traction. The company was formed in November 2015 by HighCape Partners, a growth equity fund focused on commercial-stage life sciences companies. Deerfield Management Co. joined HighCape in providing capital for the transaction. Aziyo develops customized tissue products for use in orthopedic, spinal, sports medicine, and dermal applications.
In February, Biogen Inc. (NASDAQ: BIIB) completed the previously announced spin-off of its global hemophilia business. The new company, known as Bioverativ (NASDAQ: BIVV), is an independent, publicly traded global biotechnology company focused on hemophilia and other rare blood disorders.
The Physician Medical Group sector started off the year strong and hasn’t lost any momentum as physician groups continue seeking scale to survive. As of May 26, 2017, 77 deals have been announced. The largest disclosed deal was Optum’s (NYSE: UNH) $3.3 billion acquisition of Surgical Care Affiliates, Inc. (NASDAQ: SCAI) in January.
Hospital transactions suddenly sped up in May 2017. Deals are now coming from the private equity-sponsored segment, while the publicly traded chains are mostly unwinding their 2013 acquisitions.